China Xinhuanet.com, July 19 (Reporter Chen Jing) Primary liver cancer is one of the most common malignant tumors in China, ranking second in the cause of tumor death. The reporter learned on the 19th that the Chinese Society of Clinical Oncology (hereinafter referred to as CSCO) officially announced the highly anticipated 2020 version of the "CSCO Guidelines for the Diagnosis and Treatment of Primary Liver Cancer" (hereinafter referred to as the "Guide"), not only in the field of first- and second-line treatment of liver cancer. Multiple targeted and immune new drugs and combined treatment programs have also increased the composition and discussion of MDT multidisciplinary collaboration in liver cancer diagnosis and treatment. This means that in the future, liver cancer patients will receive more standardized diagnosis and treatment.
The 2020 version of the Guide published this time incorporates the latest advances in evidence-based medicine and updates innovative treatment concepts. Professor Zhou Jian, chairman of the Liver Cancer Special Committee of the China Anti-Cancer Association and vice president of Zhongshan Hospital affiliated to Fudan University, said that the new "Guide" is of great significance for improving the diagnosis and treatment of clinicians and promoting the standardized diagnosis and treatment of primary liver cancer.
It is reported that Professor Qin Shukui, chairman of the CSCO liver cancer expert committee and chief physician of the Nanjing Jinling Hospital Cancer Center, said in an interview that unlike European and American countries, Chinese liver cancer has a high degree of heterogeneity in the etiology and treatment strategy.
The Chinese Society of Clinical Oncology (hereinafter referred to as CSCO) officially announced the highly anticipated 2020 version of "CSCO Guidelines for the Diagnosis and Treatment of Primary Liver Cancer." Chen Jingshe
Qin Shukui said that the onset of liver cancer is hidden, and early diagnosis is very difficult; Chinese patients with liver cancer often have basic liver disease, which is difficult to treat, and advanced patients have limited treatment options and a poor prognosis. The early screening rate of liver cancer in China is not high. About 85% of Chinese patients are already in the middle and advanced stages at the time of treatment, and the best opportunity for treatment is lost.
Qin Shukui bluntly stated that the median survival time of patients with advanced hepatocellular carcinoma is about 10 months, and the 5-year survival rate is only about 12%, which is significantly different from Asian countries such as Europe, America or Japan. The majority of patients are looking forward to more safe and effective innovative treatments to significantly improve the life cycle and quality of life.
According to Professor Zhou Jian, this version of the "Guide" adjusts the immunotherapy in the field of postoperative adjuvant therapy; there are corresponding indication expansions and updates in the areas of intervention, radiotherapy and ablation; antiviral therapy has also been revised in this update . According to Professor Qin Shukui, the side effects of immunotherapy with small side effects and obvious therapeutic effects are currently the focus of global cancer treatment. The exploration of joint programs has brought new hope to liver cancer patients.
The composition and discussion of the Multidisciplinary Collaborative Team (MDT) for diagnosis and treatment of liver cancer is also one of the highlights of the update of the "Guide". Professor Zhou Jian said that the MDT diagnosis and treatment model can take advantage of the multidisciplinary collaboration of relevant departments in the field of liver cancer diagnosis and treatment, avoid the limitations of single-diagnosis and treatment, is conducive to the selection of reasonable treatment methods and drugs, and requires compliance with high-level evidence-based medical evidence. Consider the individual differences of patients. (Finish)